Previous close | 5,462.56 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 5,442.43 - 5,442.43 |
52-week range | 2,925.18 - 5,442.43 |
Volume | |
Avg. volume | 125 |
Market cap | N/A |
Beta (5Y monthly) | 1.20 |
PE ratio (TTM) | 44.81 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SWORDS, Ireland, May 14, 2024--Trane Technologies (NYSE: TT), a global climate innovator, is accelerating growth and delivering continued, industry-leading financial performance while advancing the company’s bold 2030 Sustainability Commitments.
MOUNTAIN VIEW, Calif. & MINNEAPOLIS, May 09, 2024--Range Energy (Range), the hardware company bringing powered trailers to the commercial trucking market, and Thermo King, a leader in sustainable transport temperature control solutions and strategic brand of Trane Technologies (NYSE: TT), today announced a strategic collaboration to advance the commercialization of electric refrigerated trailers in the Americas.
Acepodia (6976:TT), a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms to address gaps in cancer care, today announced preliminary data from its Phase 1 dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin's lymphoma (NHL).